Research Article
Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia
Table 2
Cox proportional hazards model for OS and PFS in AML patients.
| Variables | OS | PFS | HR (95% CI) | | HR (95% CI) | |
| Age | 1.018 (1.001-1.035) | 0.040 | 1.008 (0.991-1.026) | 0.335 | Sex (male vs. female) | 0.811 (0.547-1.203) | 0.298 | 0.752 (0.480-1.177) | 0.212 | WBC counts | 1.007 (1.002-1.011) | 0.002 | 1.007 (1.002-1.011) | 0.006 | BM blasts percentage | 1.009 (0.998-1.020) | 0.127 | 1.002 (0.989-1.016) | 0.769 | ELN risk stratification | | 0.006 | | 0.018 | (intermediate/adverse vs. favorable) | 2.720 (1.341-5.518) | | 2.521 (1.173-5.419) | | Induction therapy | | 0.001 | | 0.474 | (intensive vs. nonintensive) | 0.371 (0.211-0.654) | | 0.736 (0.318-1.702) | | HSCT (yes vs. no) | 0.508 (0.304-0.848) | 0.010 | 1.149 (0.644-2.052) | 0.637 | FZD6 expression | 1.264 (1.025-1.559) | 0.028 | 1.081 (0.853-1.370) | 0.518 |
|
|
Abbreviations: OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence interval.
|